

## SIMPONI ARIA (GOLIMUMAB)

**INFUSION ORDERS** 

FAX: 470.922.3656 | PHONE: 470.377.6400

PATIENT INF	ORMATION:	Fax completed form, ins	urance information, and clinical	documentation to 470.922.3656	
Patient Name:			DOB: Pł	none:	
Patient Status:	New to Therapy	Continuing Therapy	Next Treatment Date:		
MEDICAL INF	ORMATION				
Diagnosis:	Rheumatoid Arth Ankylosing Spon Other:		c Arthritis		
ICD-10 Code:					
PatientWeight:	lbs.(required)	Allergies:			
THERAPY OR	DER				
Simponi Aria:					
2mg/kg IV ev	very 8 weeks x 1 ye	nen every 8 weeks x 1 ear			
Lab Orders:       Frequency:       Every infusion       Other:         TB QFT screening yearly       Baseline HepBcAB total       Other:					
Required labs to be drawn by:					
Other orders:					
<ul> <li>&gt;30kg (&gt;</li> <li>15-30kg</li> <li>Diphenhydram</li> <li>Refer to physic</li> </ul>	based on patient weig 66lbs): EpiPen 0.3m (33-66lbs): EpiPen J hine: Administer 25-5 cian order or institution 5 1-20mL pre/post inf	g or compounded syringe r. 0.15mg or compounded 0mg orally OR IV (adult onal protocol for pediatric		repeat in 5-10 minutes x1	
By signing this form and utiliz	ing our services, you are authoriz		o serve as your prior authorization and spe	ecialty pharmacy designated	
		anies, and to select the preferred site of o Sianature:		Date:	
Provider NPI:	Phone:	Fax:	Contact Pe	Date: erson:	
		g site of care (if checked	, please list site of care):		
PREFERRED	LOCATION				
City:	State:		View our locations here:		
IMPORTANT NOTICE: This	fax is intended to be delivered	BIOCAREINFUSIO		property, or exempt from disclosure under	

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



## COMPREHENSIVE SUPPORT FOR SIMPONI ARIA (GOLIMUMAB) THERAPY

PATIENT INFORMATION:				
Patient Name: DOB:				
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL				
Include <u>signed and completed order (MD/prescriber</u> to complete page 1)				
Include patient demographic information and insurance information				
Include patient's medication list				
<ul> <li>Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy</li> <li>Has the patient had a documented contraindication/intolerance or failed trial of a DMARD, NSAID, or conventional therapy (i.e., MTX, leflunomide)?</li></ul>				
Does the patient have a contraindication/intolerance or failed trial to at least one biologic (i.e., Humira, Enbrel, Stelara, Cimzia)?				
Include labs and/or test results to support diagnosis (attach results)				
Rheumatoid factor				
Anti-Cyclic citrullinated peptide (anti-CCP) CRP and/or ESR				
If applicable - Last known biological therapy: and last date received: If patient is switching to biologic therapies, please perform a wash-out period of weeks prior to starting Simponi Aria.				
Other medical necessity:				
REQUIRED PRE-SCREENING				
☐ TB screening test completed within 12 months - attach results ☐ Positive □ Negative				
Hepatitis B screening test completed (Hepatitis B antigen) - attach results Positive  Negative				
*If TB or Hepatitis B results are positive - please provide documentation of treatment or medical clearance, and a negative CXR (TB+) Biocare Infusion will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any				

additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

## Please fax all information to (470) 922-3656 or call (470) 377-6400 for assistance

BIOCAREINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.